ICU sedation, delirium & recovery
Haloperidol vs. placebo for the treatment of delirium in intensive care unit (ICU) patients: a pre-planned, secondary Bayesian analysis of the AID–ICU trial
Authors' conclusion
We found high probabilities of benefits and low probabilities of harm with haloperidol treatment compared with placebo in acutely admitted, adult ICU patients with delirium for the primary and most secondary outcomes.
Study context
- Population
- Acutely admitted adult ICU patients with delirium
- Comparison
- Haloperidol vs placebo
- Primary endpoint
- Days alive and out of hospital
- Follow-up
- Up to day 90
Methodological detailspre-planned, Bayesian, blinded, placebo-controlled, weakly informative priors, sensitivity analyses using other priors
- Pre-planned
- Bayesian
- Blinded
- Placebo-controlled
- Weakly informative priors
- Sensitivity analyses using other priors
Primary result
As reported in the abstract
Mean difference, haloperidol vs placebo
2.9 days (95% CrI - 1.1 to 6.9) (95% CrI)
Probability of any benefit
92%
Probability of clinically important benefit
82%
Secondary outcomes
Mortality · up to day 90
- Risk difference, haloperidol vs placebo (95% CrI)
- - 6.8 percentage points (95% CrI - 12.8 to - 0.8)
- Probability of any benefit
- 99%
- Probability of clinically important benefit
- 94%
Sensitivity analyses with different priors
- Probability of benefit with haloperidol
- more than 83%
- Probability of harm with haloperidol
- less than 17%
- Results consistent across priors
Safety
Serious adverse reactions · up to day 90
- Adjusted risk difference, haloperidol vs placebo
- 0.3 percentage points (95% CrI - 1.3 to 1.9) (95% CrI)
- Probability of no clinically important difference
- 98%
Original publication
Haloperidol vs. placebo for the treatment of delirium in ICU patients: a pre-planned, secondary Bayesian analysis of the AID–ICU trial. Intensive Care Med. Published 27 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →